Kallyope links oral obesity combo to 3% weight loss, rejigs pipeline as migraine asset advances
Kallyope has slipped out results from a phase 2 trial of its obesity candidates, linking the combination of the two oral prospects to weight loss of 2.9% after 13 weeks of treatment.
Kallyope has slipped out results from a phase 2 trial of its obesity candidates, linking the combination of the two oral prospects to weight loss of 2.9% after 13 weeks of treatment.
